ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Berlin, BE, DEU:

Locations recently updated

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Berlin, Germany and 73 other locations

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Enrolling
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Berlin, Germany and 65 other locations

Locations recently updated

study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...

Enrolling
Multiple Sclerosis
Drug: Ofatumumab
Drug: First line DMT

Phase 3

Novartis
Novartis

Berlin, Germany and 49 other locations

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Potsdam, Germany and 122 other locations

and female participants aged 18 to 60 years with relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple...

Active, not recruiting
Multiple Sclerosis
Drug: SAR443820
Other: Placebo

Phase 2

Sanofi
Sanofi

Berlin, Germany and 40 other locations

The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS...

Enrolling
Amyotrophic Lateral Sclerosis
Drug: QRL-201 - Dose 2
Drug: QRL-201 - Dose 5

Phase 1

QurAlis

Berlin, Germany and 10 other locations

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab
Drug: Antihistamine

Phase 3

Roche
Roche

Berlin, Germany and 125 other locations

relapse rate (ARR) in participants with relapsing forms of MSSecondary Objective:To assess efficacy of SAR442168 compared to teriflunomide (...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo to match Teriflunomide
Drug: Teriflunomide HMR1726

Phase 3

Sanofi
Sanofi

Berlin, Germany and 185 other locations

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple...

Active, not recruiting
Multiple Sclerosis, Primary Progressive
Drug: Placebo matched to ocrelizumab
Drug: Fenebrutinib

Phase 3

Roche
Roche

Berlin, Germany and 192 other locations

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Fenebrutinib

Phase 3

Roche
Roche

Berlin, Germany and 167 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems